Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Glasdegib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
Most Recent Events
- 26 Aug 2024 Planned End Date changed from 30 Sep 2025 to 30 Jun 2027.
- 26 Aug 2024 Planned primary completion date changed from 5 Apr 2024 to 30 Jun 2025.
- 06 Feb 2024 Planned primary completion date changed from 31 Mar 2024 to 5 Apr 2024.